CureDuchenne - Together we Can CureDuchenne
January 2014
spacer

Prosensa Updates

Prosensa logo

There have been several recent developments from Prosensa. Prosensa recently announced that they have regained rights to drisapersen from GSK and will retain rights to all other programs for the treatment of Duchenne. This will allow Prosensa an opportunity to advance their Duchenne portfolio.

Prosensa also reported on the initial findings from the further clinical data analyses of drisapersen. The results suggest that treating the disease earlier and longer shows a delay in the progression of the disease. They conducted a patient webinar on January 21.

For more detailed information about Prosensa news, please see below.

Powered By Convio